Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Sees Large Growth in Short Interest

Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Rating) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 467,100 shares, an increase of 5.5% from the February 13th total of 442,600 shares. Based on an average daily volume of 65,100 shares, the short-interest ratio is presently 7.2 days. Approximately 2.1% of the shares of the stock are short sold.

Eton Pharmaceuticals Trading Down 4.9 %

ETON opened at $3.90 on Friday. Eton Pharmaceuticals has a one year low of $1.95 and a one year high of $4.50. The stock has a market capitalization of $98.67 million, a PE ratio of -11.71 and a beta of 1.45. The business’s 50 day moving average price is $3.60 and its 200 day moving average price is $2.93. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.42 and a current ratio of 3.52.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ETON. JPMorgan Chase & Co. purchased a new stake in shares of Eton Pharmaceuticals during the first quarter worth $106,000. State Street Corp increased its position in shares of Eton Pharmaceuticals by 9.3% during the first quarter. State Street Corp now owns 91,603 shares of the company’s stock worth $399,000 after acquiring an additional 7,831 shares during the period. PDT Partners LLC purchased a new stake in shares of Eton Pharmaceuticals during the first quarter worth $102,000. Goldman Sachs Group Inc. purchased a new stake in shares of Eton Pharmaceuticals during the first quarter worth $77,000. Finally, Virtu Financial LLC purchased a new position in Eton Pharmaceuticals in the second quarter valued at $67,000. 25.09% of the stock is currently owned by institutional investors and hedge funds.

Eton Pharmaceuticals Company Profile

(Get Rating)

Eton Pharmaceuticals, Inc engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection.